Skip to main content

Supported By

Best Practices in Ovarian Function Suppression in Breast Cancer

Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
By Emily M. Beard, RN, BSN, OCN, CBCN; Abbey J. Kaler, MS, APRN, FNP-C; Mohammed A. Jaloudi, MD
Breast Cancer
Best Practices in Ovarian Function Suppression in Breast Cancer
Invasive breast cancer will be diagnosed in an estimated 300,000 American women in 2023. Early screening and targeted treatment have improved overall survival since the late 1980s, but breast cancer remains the second most common cause of cancer death in women, occurring in 1 in 39 women. Read More ›